Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01677858 | A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma(CHAMPION 1) | completed | Phase 1 / Phase 2 | 116 | AmgenINDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT04552743 | MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma | completed | Phase 2 | 25 | Surbhi Sidana, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT00599495 | Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT | completed | Phase 2 | 50 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Sep 2, 2022 | clinicaltrials |
| NCT00784823 | Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma(Mel-Vel) | completed | Phase 1 / Phase 2 | 32 | Hackensack Meridian HealthOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT01119066 | HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | completed | Phase 2 | 422 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT02384083 | Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients | completed | Phase 1 / Phase 2 | 47 | PETHEMA FoundationOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT02272803 | Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan | completed | Phase 2 | 82 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT02977494 | Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment(GMMG-DANTE) | completed | Phase 2 | 22 | Universitätsklinikum Hamburg-EppendorfOTHER | 2 | May 31, 2022 | clinicaltrials |
| NCT01849783 | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | completed | Phase 2 | 41 | Margarida Magalhaes-SilvermanOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT01463670 | Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance | completed | Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT01658241 | Panobinostat Biological Correlates Study(VEG VCA1) | completed | Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03964688 | Effect of Vitamin C in Autologous Stem Cell Transplantations(VICAST) | completed | Phase 2 | 47 | Maastricht University Medical CenterOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT01989598 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03697629 | A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 40 | Canadian Myeloma Research GroupOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT01496118 | Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 80 | SCRI Development Innovations, LLCOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT02424851 | Optimising Renal Outcome in Myeloma Renal Failure(OPTIMAL) | completed | Phase 2 | 31 | Oxford University Hospitals NHS TrustOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT04065789 | Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients(KyDaR) | completed | Phase 2 | 41 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jan 27, 2022 | clinicaltrials |
| NCT01962792 | Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 84 | Pharmacyclics LLC.INDUSTRY | 2 | Dec 21, 2021 | clinicaltrials |
| NCT02086552 | Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT01131169 | Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions | completed | Phase 2 | 66 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT01793051 | Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma | completed | Phase 2 | 88 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT01421186 | A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 91 | MorphoSys AGINDUSTRY | 2 | Nov 16, 2021 | clinicaltrials |
| NCT00177047 | Autologous Transplant for Multiple Myeloma | completed | Phase 2 / Phase 3 | 363 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT01054144 | Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 13, 2021 | clinicaltrials |
| NCT02951819 | A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma | completed | Phase 2 | 101 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT02169791 | Nonmyeloablative Haploidentical Transplant Followed by MLN9708 | completed | Phase 2 | 29 | Northside Hospital, Inc.OTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT02045017 | Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency | completed | Phase 2 | 81 | CelgeneINDUSTRY | 8 | Aug 27, 2021 | clinicaltrials |
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Molecular Partners AGINDUSTRY | 6 | Aug 25, 2021 | clinicaltrials |
| NCT00421525 | Phase I/II Study of hLL1 in Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01720875 | Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)(MUKfour) | completed | Phase 2 | 16 | University of LeedsOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | completed | Phase 1 / Phase 2 | 38 | AbbVieINDUSTRY | 1 | Aug 2, 2021 | clinicaltrials |
| NCT03665155 | First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody | completed | Phase 1 / Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT04439240 | Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2021 | clinicaltrials |
| NCT02703779 | Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) | completed | Phase 2 | 101 | Siddhartha GangulyOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT02499081 | UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment | completed | Phase 2 | 20 | University of ArkansasOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT02420223 | Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients | completed | Phase 2 | 25 | Medical College of WisconsinOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT00151203 | Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma | completed | Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | May 27, 2021 | clinicaltrials |
| NCT00538733 | Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma(T-BiRD) | completed | Phase 2 | 26 | Weill Medical College of Cornell UniversityOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT01018979 | Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | completed | Phase 2 | 19 | GPCR Therapeutics, Inc.INDUSTRY | 1 | May 11, 2021 | clinicaltrials |
| NCT01177735 | Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma | completed | Phase 2 | 71 | University of ArkansasOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT01458288 | A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease | completed | Phase 2 | 12 | GPCR Therapeutics, Inc.INDUSTRY | 1 | Apr 19, 2021 | clinicaltrials |
| NCT02104427 | PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | completed | Phase 2 | 12 | GPCR Therapeutics, Inc.INDUSTRY | 1 | Apr 19, 2021 | clinicaltrials |
| NCT01045460 | Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma(aMILs) | completed | Phase 2 | 36 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT04439214 | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2021 | clinicaltrials |
| NCT00773838 | Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) | completed | Phase 2 | 143 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 1, 2021 | clinicaltrials |
| NCT03262389 | Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma | completed | Phase 2 | 10 | Michael C Roarke, MDOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT01402284 | Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02078102 | A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma | completed | Phase 2 | 38 | Sherif S. FaragOTHER | 1 | Feb 21, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 23, 2022source: clinicaltrials